Abstract. Regulatory administrative database systems within the Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) are essential to supporting its core mission, as a regulatory agency. Such systems are used within FDA to manage information and processes surrounding the processing, review, and tracking of investigational and marketed product submissions. This is an area of increasing interest in the pharmaceutical industry and has been a topic at trade association conferences (Buckley 2012). Such databases in CBER are complex, not for the type or relevance of the data to any particular scientific discipline but because of the variety of regulatory submission types and processes the systems support using the data. Commonalities among different data domains of CBER's regulatory administrative databases are discussed. These commonalities have evolved enough to constitute real database convergence and provide a valuable asset for business process intelligence. Balancing review workload across staff, exploring areas of risk in review capacity, process improvement, and presenting a clear and comprehensive landscape of review obligations are just some of the opportunities of such intelligence. This convergence has been occurring in the presence of usual forces that tend to drive information technology (IT) systems development toward separate stovepipes and data silos. CBER has achieved a significant level of convergence through a gradual process, using a clear goal, agreed upon development practices, and transparency of database objects, rather than through a single, discrete project or IT vendor solution. This approach offers a path forward for FDA systems toward a unified database.
BACKGROUND
The Center for Biologics Evaluation and Research (CBER) is the Food and Drug Administration (FDA) center with regulatory oversight of biological products including vaccines, blood and blood products, and cells, tissues, and gene therapies for the prevention, diagnosis, and treatment of human diseases, conditions, or injury (2) . This makes it unique among FDA centers and challenging for the variety of areas of responsibility and authority under which it must operate (3). The diverse array of products are subject to an equally diverse array of regulations, statutes, and negotiated user fee performance goals. In addition, these regulations and performance goals vary across the product lifecycle, from investigational through post-marketing and surveillance. It must therefore receive and process a variety of regulatory applications. For these reasons, the databases that support these applications and their associated review processes can be quite complex.
These systems not only must track the actual submissions CBER receives, but their metadata such as what is being added or modified in the product or manufacture, workflow, review committee membership and roles, review decisions, precedence, internal and external communications, and details surrounding the product, manufacture, usages, dosage forms, interfaces to the documents, and submissions in CBER's electronic document room, as well as history.
CBER's authority, actions it can take, reporting obligations, and how it must manage the review process referred to as "Managed Review" differs across product classes and application type as do the content and structure of the applications themselves. These include the Biologics License Application (BLA) This diverse environment presents a challenge not only in the management and tracking of regulatory applications and review but also in the development of IT systems that support them. The focus here is the databases underlying the supporting systems that capture metadata about the regulatory applications and support the review process.
CHARACTERIZATION OF SYSTEMS AND THEIR UNDERLYING DATABASES
There are seven major IT systems that support regulatory applications tracking and review and all pertain to this discussion. The databases can be quite complex. RMS/BLA alone, for example, fulfills more than a thousand documented user requirements and is comprised of more than 35 major screens, 40 queries, and 50 reports. The physical database consists of about 200 tables, 350 triggers, 40 packages, and 20 views.
The data underlying these systems reside within the same Oracle database instance, but are partitioned into separate schema accounts. An Oracle schema is a grouping of tables and other database objects by the IT system or account that owns them. The schemas were designed to be transactional, for efficient data insertion and storage as opposed to reporting. Therefore, the data models are relational and normalized, meaning that the data are spread across multiple, smaller tables, to minimize redundancy, that can then be joined together (related) in a variety of ways using common keys. However, the degree of normalization varies across schemas. Each system has reporting capability within its user interface, i.e., screens and reports, against its respective data domains and is specific to only those regulatory applications it supports.
CBER uses some popular tools for business intelligence (BI) reporting, such as Business Objects. These tools are built around a datamart principle whereby the data from the live, transactional systems are decoded, aggregated, and pieced together into simpler structures (transformed) and then ported into a separate database for reporting. The reporting database must then be refreshed at regular intervals. This principle facilitates data mining and analysis and is often referred to as "OnLine Analytical Processing" (OLAP). At present, the usage of OLAP in CBER is limited mostly to adverse events reporting and analysis. What does exist that is related to the regulatory application systems is confined to each system and regulatory application type. This tool and approach provide much value to CBER but, by its very nature, would not demonstrate convergence of the transactional databases themselves that underlie the different IT systems. Further, government agencies are beginning to look beyond basic data warehousing and reporting toward Master Data Management (MDM) strategy which will be discussed (4).
SILOS BY DESIGN
It is not unusual for organizations to find themselves with multiple and disparate information systems. Such an outcome often breeds stovepipes, or more accurately, isolated silos of data (5) . This predicament has been attributed to a variety of reasons, most often a command-and-control-oriented culture (Rosen) and IT governance (6) .
However, organizations arrive at such a state for practical reasons as well. As CBER has evolved over the years, so too have the regulations, statutes, agreements, and the IT systems that support its mission. Separate IT Fig. 1 . CBER regulatory systems pertaining to this article in the context of the phases of the pharmaceutical product lifecycle they support systems supporting different areas of need were a natural outcome as regulatory application types, and the organization itself were, at one time, partitioned along similar lines of separation. Separate databases underlying these systems were developed and modified over time, as needs arose, by different sets of stakeholders working in separate organizational units, drawing from different sets of requirements, all working to meet different deadlines. IT system development in CBER conforms most closely to the "spiral model," a continuous cycle of enhancement and deployment that has proceeded along different timelines for the aforementioned reasons but also because of the nature of funding sources.
Targeted funding brought needed resources but also brought challenges to an otherwise, deliberative, unified design approach. Funding is often highly targeted as the legislation behind each funding source specified areas to be addressed and tracking and reporting requirements, and drove development schedules. This all but precluded the use of a fund beyond its immediate mandate. Even with strong IT governance, development in one domain could not await the development in another when one had been legislated and already funded. Therefore, separate silos of data are often an unavoidable outcome of such a dynamic environment.
Some To fulfill PDUFA, for example, it would have been unacceptable to use the accompanying funds on IT systems or data domains not covered under the Act, such as whole blood and blood components for transfusion, devices, and compliance activities. Project Bioshield specified funding for implementation of the Emergency Use Authorization (EUA). It would have been unacceptable for delays as part of a larger unified database vision to delay support for the EUA. 
CONVERGENCE
Reorganizations gradually brought together different stakeholders as they mixed together different areas of regulatory application review. Staff found themselves managing multiple application types and having to navigate across multiple IT systems. Differences among these systems became easily apparent and troublesome. Realization of this prompted the CBER vision of a Vast Regulatory Database in 1997. Several outputs of this vision have endured and have gradually driven the underlying databases toward a significant degree of harmonization, even as FDA and IT staff have turned over and development has continued independently within each IT system team. Development under the spiral model enabled these outputs to be gradually introduced with successive versions of each system. Although greater harmonization is still desired, enough has occurred in key areas to provide important value to CBER for review management and business intelligence.
Notably, some of the key areas are consistent with entities described in Oracle's MDM (7), which may help explain their value to CBER. Commonalities now exist across a number of data domains, database objects, and architecture to substantiate convergence and therefore real progress toward the vision of a unified database.
Database convergence in CBER is evident in a number of areas. This was accomplished largely because development teams agreed to make their objects visible (transparent) to each other, exercise a common naming convention for their objects, format similar data types similarly, and publicize useful code for reuse. There are still profound differences among database schemas, e.g., varying degrees of normalization (some highly relational and codified) and differing data domain models. However, the aforementioned master data nature of the commonalities minimizes the importance of these differences with respect to business intelligence as the MDM model suggests. For example, shared tables exist for valid values and pick lists, reviewer names, review organizations, review schedule types, company contacts, manufacturing facilities and addresses, and product names. Critical dates are stored and named in similar ways such as dates for receipt, review status, and completions. Due dates are stored physically different across schemas but logically similar, e.g., either as values in physical tables (in RMS/BLA) or as derived values encapsulated in database objects such as a view (in BIRAMS). These objects are similarly named across schemas and kept conspicuous with public synonyms. A submission numbering and hierarchy scheme ensures unique numbering and parent-child relationships across application databases, the submission tracking number (STN).
All database schemas underlying these various IT systems reside within the same database instance. This allowed for greater transparency, that is, an awareness and understanding of useful database objects by the developers of the different systems that could then be shared among them. Reuse of existing objects, such as tables, views, and functions, is often pursued as the path of least resistance when developers are aware such assets exist (8) . This "object transparency" facilitated the shared use in CBER of existing database objects by the different development teams.
Establishing master data is not without its challenges. For example, some data domains that would provide great value as master data remain a challenge. Legal entity continues to be difficult to harmonize across databases. Entities such as sponsors of INDs can be a person or an institution and can be different than an applicant of a new drug application, or a contract facility, or the manufacturer of its source material. These legal entities often merge, split, or are renamed, and some are subsidiaries to others. Their applications are often submitted to FDA using variations of the same entity name. Therefore, harmonizing and managing these across departments, application types, and systems is still a work in progress.
AFFIRMATION
Database convergence is becoming evident from a growing number of uses that are benefiting CBER in new ways. Queries written directly against the live, transactional data, across schemas, use a number of the above master data commonalities. These offer greater BI than the traditional reports within each specialized IT system.
The following sample Structured Query Language (SQL) code is used within the database and is evidence of MDM. It fetches the complete review committee list for each IND application from the BIRAMS database schema using master data. The master data here are actually a function which selects against a shared table of Center review staff, the CBER person table. Such functions are provided within each database application schema so these essential data can be derived in the same way across the different regulatory systems. Figure 2 presents the query as an execution diagram.
SELECT DISTINCT folder_id stn, f_get_ind_reviewers(folder_id) committee FROM [BIRAMS schema].ira_data_vw;
The function f_get_ind_reviewers is used by the query and makes use of the master data, person. Note its use in an excerpt of the function's code below. A comprehensive review workload can be derived across schemas (across databases) by making use of some of the master data objects discussed above (Fig. 3) (data presented here are fictional). For each reviewer, the graph in Fig. 3 presents a composite bar of the number of submissions currently under their review by application type. In the example, it appears that reviewers L and N have the greatest workload followed by reviewers K and M. Another variation of this workload tool is also employed which adds a time dimension, i.e., workload by reviewer by month that their submissions are coming due for a regulatory action (not shown here).
However, some application types will require more effort to review than others, e.g., an original BLA or NDA versus an annual report. Weightings can be applied by application type to further aid in gauging workload. Just what each numeric weighting should be is not the subject of this paper but would be subject to the knowledge and discretion of a frontline supervisor and will vary across review disciplines, e.g., clinical review, promotional materials review, regulatory review. Weightings were applied to the sample data from above giving some application types a greater factor than others (Fig. 4) . Reviewer M now appears to have the greatest workload followed by reviewers N than L. More importantly, however, this reveals that 70% of the overall weighted review workload is being handled by 32% of the review staff. Such a disproportionate dependency upon so few reviewers suggests a risk in review performance. It can inform decisions of work redistribution, cross-training, and help in gauging management effectiveness in the distribution of work across their staff. Such a model can also be used for comparisons with future distributions for planning and management performance. This tool is currently being employed within the Clinical Review Branch and Regulatory Project Management Branch of CBER's Office of Blood Research and Review.
Applying another dimension, product, provides another way to detect risk to the review process (Fig. 5) . Figure 5 presents the number of applications received by product within a specified period of time (cohort) against the number of unique product reviewers serving on the committees for those submissions. Such a presentation can help inform in the adjustment of review capacity to where it is most needed, to those product areas with most applicant submission activity. It can also expose risk in review capacity or understaffing in a product area. In the example, products x, y, and z may be good candidates for more review staff participation since only a few reviewers were associated with these products that receive a disproportionately higher number of submissions (STNs are a measure of submission counts).
Another output that makes use of master data and that has been useful to CBER is a comprehensive list of review obligations and due dates across application databases, example not shown here. Such reports are up to the minute because they run against the live, transactional databases. Such queries are used regularly to ensure managers have complete visibility of all pending applications and their due dates but have also been used on multiple occasions in preparation for snow storms and government shutdowns. 
DISCUSSION AND CONCLUSIONS
For large, disparate database systems in FDA, unification through gradual convergence can be accomplished to a degree that is sufficient enough to facilitate real-time business intelligence. This may be best approached as a common goal, using agreed upon standards and practices and by focusing on master data. These practices and standards include identifying data domains as master data targets, object transparency, common naming conventions, code publication and reuse. This approach allows systems to continue to evolve independently and flexibly yet still converge using the data domains that count, master data. Such an approach may become especially important as organizations migrate toward new cloud services. Former Health and Human Services' Chief Information Officer John Teeter noted that "The danger of the cloud is that it could just move our stovepipes to a more accessible environment" (9) . Gradual convergence using master data may be a path forward whereby each IT system can remain responsive to its unique and changing mandates and continue to support FDA's mission. Notice The findings and conclusions in this article have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy. All data presented in this paper are for demonstration purpose and are fictional. Actual schema names have been redacted and substituted in brackets.
